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OBJECTIVE — There is debate over the most appropriate adiposity markers of obesity-
associated health risks. We evaluated the relationship between fat distribution and high-
sensitivity C-reactive protein (hs-CRP), independent of total adiposity.
RESEARCH DESIGN AND METHODS — We studied 350 people with abdominal
adiposity(waist-to-hipratio[WHR]0.9inmaleand0.85infemalesubjects)and199control
subjects (WHR 0.9 in male and 0.85 in female subjects) matched for BMI and age. We
measured hs-CRP and major cardiovascular risk factors.
RESULTS — ParticipantswithabdominaladiposityhadBMIsimilartothatincontrolsubjects
(24.8  2.5 vs. 24.7  2.2 kg/m
2, respectively), but signiﬁcantly higher waist circumference
(96.4  6.0 vs. 83.3  6.7 cm; P  0.01) and WHR (1.07  0.08 vs. 0.85  0.05; P  0.001).
Compared with the control subjects, participants with abdominal adiposity had an adverse
cardiovascular risk factor proﬁle, signiﬁcantly higher hs-CRP (1.96  2.60 vs. 1.53  1.74
mg/dl; P  0.01), and a twofold prevalence of elevated CRP values (3 mg/dl).
CONCLUSIONS — In nonobese people, moderate abdominal adiposity is associated with
markers of subclinical inﬂammation independent of BMI.
Diabetes Care 32:1734–1736, 2009
T
here is debate over the most appro-
priate adiposity markers of obesity-
associated health risks. Large
studies have shown that measures of ab-
dominal adiposity, such as waist circum-
ferenceandwaist-to-hipratio(WHR),are
more closely associated with the risk of
diabetes, cardiovascular disease, and
death than BMI, which is a measure of
general adiposity (1,2). The excess car-
diometabolicriskassociatedwithabdom-
inal adiposity is only partly explained by
establishedriskfactors;additionallessex-
tensively explored mechanisms may in-
clude systemic low-grade inﬂammation
(3). Indeed, high-sensitivity C-reactive
protein (hs-CRP) is a powerful marker of
cardiovascular risk despite normal choles-
terol levels, thus expanding the indication
for use of statins beyond hyperlipidemia,
because these drugs lower both choles-
terol and CRP levels (4). To assess the im-
pactofabdominaladiposityonlow-grade
inﬂammation independent of BMI, we
comparedhs-CRPinpeoplewithorwith-
out abdominal adiposity but with the
same BMI.
RESEARCH DESIGN AND
METHODS— The analysis is based
on a case-control design. Among 1,252
subjects undergoing health screenings
(5), we selected 350 consecutive people
with abdominal adiposity (WHR 0.9 in
male and 0.85 in female subjects) and
199 control subjects (WHR 0.9 in male
and 0.85 in female subjects) (6)
matched for BMI ( 1 kg/m
2) and age (
5 years) within sex strata. Exclusion crite-
ria were diabetes, BMI 35 or 20 kg/
m
2, use of statins or nonsteroidal anti-
inﬂammatory drugs, acute or chronic
infections (assessed by history, use of
drugs,andclinicalexamination),andpre-
vious cardiovascular disease. We mea-
sured anthropometry, supine blood
pressure, fasting plasma glucose levels,
uric acid, triglycerides, total and HDL
cholesterol levels (standard methods), in-
sulin (radioimmunoassay), ﬁbrinogen
(immunonephelometry), and hs-CRP
(Tina-Quant; Roche). Insulin resistance
was also calculated using homeostasis
model assessment of insulin resistance
(HOMA-IR). Detailed study procedures
have previously been published (5). The
local ethics committee approved the
study, and participants gave informed
consent. Data were analyzed by unpaired
Student’s t test, 
2, Pearson correlation,
and multivariate regression.
RESULTS— Participantswithabdom-
inal adiposity had age and BMI similar to
that in control subjects (24.8  2.5 vs.
24.7  2.2 kg/m
2), but signiﬁcantly
higher waist circumference and WHR
(Table 1). CRP was signiﬁcantly higher in
participants with abdominal adiposity
than in control subjects; accordingly, in
the group with abdominal adiposity, the
proportion of people with elevated CRP
(3 mg/dl) was twice that in the control
subjects (Table 1). Nine case subjects
(1.9%) and one control subject (0.5%)
had CRP 10 mg/dl, and removing these
people from analysis quantitatively atten-
uated the differences between case and
control subjects (mean  SD CRP 1.66 
1.50vs.1.431.26mg/dl,P0.07,and
19.5 vs. 9.6%, P  0.04, with CRP 3
mg/dl). The male sex was more prevalent
among case subjects; however, CRP was
similar for male and female subjects
(1.78  2.16 vs. 1.87  2.11 mg/dl; P 
0.65).Furthermore,atwo-wayanalysisof
variance did not show a signiﬁcant sex
effect or the interaction between sex and
abdominaladiposityonCRP.Peoplewith
abdominal adiposity showed an adverse
cardiometabolic risk proﬁle compared
with that in control subjects (Table 1)
(i.e., signiﬁcantly higher triglycerides,
blood pressure, HOMA-IR, lower HDL
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lence of metabolic syndrome (Adult
Treatment Panel III [ATPIII]). Smoking
status and plasma ﬁbrinogen were com-
parable in the two groups. hs-CRP was
signiﬁcantly correlated with BMI in both
case (r  0.23; P  0.01) and control
subjects (r  0.17; P  0.02); however,
multivariate analyses conﬁrmed a signiﬁ-
cant association of abdominal adiposity
with either CRP (continuous variable) or
elevated CRP (3 mg/dl) independent of
BMI,age,sex,andmeasuredcardiovascu-
lar risk factors.
CONCLUSIONS — The study shows
that in healthy nonobese people, abdom-
inal adiposity is associated with hs-CRP,
independent of age and BMI, which is a
measure of total adiposity. hs-CRP values
and the proportion of people with ele-
vated hs-CRP [i.e., 3 mg/dl, a value as-
sociated with increased cardiovascular
risk (7)] are signiﬁcantly higher in those
with abdominal adiposity than in control
subjects, notwithstanding a superimpos-
able BMI. A signiﬁcant correlation be-
tween BMI and hs-CRP levels is observed
in both groups, thus conﬁrming expected
ﬁndings and conferring internal consis-
tency with our results. The excess cardio-
metabolic risk associated with abdominal
adiposityisonlypartiallyexplainedbyes-
tablished risk factors; systemic low-grade
inﬂammation may represent an addi-
tional less extensively explored mecha-
nism (3,4). Indeed, hs-CRP predicts
cardiovasculareventsinpeoplewithnon-
elevated LDL cholesterol levels (4,7). Be-
cause statins lower both cholesterol and
CRP, measuring this biomarker helps to
identifypeoplewhomaybeneﬁtfromsta-
tin treatment beyond its lipid-lowering
effect.
Given the strong association we show
between WHR and hs-CRP—indepen-
dent of BMI—and considering the difﬁ-
culty of routinely measuring hs-CRP in
the general population, WHR (although a
crude measure of abdominal adiposity)
might be proposed in nonobese people as
a surrogate marker for subclinical inﬂam-
mation or, alternatively, as a simple
means to select individuals in whom hs-
CRP should be measured to further char-
acterize their cardiovascular risk. CRP is
the most widely measured marker of sys-
temic inﬂammation; its interindividual
variance is largely due to genetic factors
(50%). However, adiposity is the other
major determinant of hepatic CRP syn-
thesis via production of proinﬂammatory
cytokines (interleukin [IL]-6, IL-1, and
tumor necrosis factor-). There is evi-
dencethatIL-6,akeydeterminantofCRP
production in hepatocytes, is secreted in
anendocrinemannerinproportiontothe
expansion of fat mass, particularly in the
abdominal region (8,9). The relation of
CRPwithfatmassandfatdistributionhas
been extensively explored with partially
conﬂicting results (10–13). Most, but not
all, studies focus on obese or morbidly
obese people in whom a differential im-
pact of total or abdominal adiposity may
be difﬁcult to evaluate. This is one of the
very few population-based studies of
nonobese people. Furthermore, unlike
previous studies, we used a case-control
design, which is particularly efﬁcient in
controlling for the confounding effect of
BMI, allowing us to compare people with
different fat distribution but the same BMI.
The cross-sectional nature of the study,
however, does not allow to determine
whether abdominal adiposity is causally as-
sociated with CPR elevation or whether the
association is mediated through other obe-
sity-associated conditions such as insulin
resistance or subclinical atherosclerosis.
Inconclusion,thestudyshowsthatin
healthy nonobese people, hs-CRP is asso-
ciated with abdominal adiposity—
evaluated as WHR—independent of BMI,
thus supporting current recommenda-
tions that in people with BMI 25.0–34.9
kg/m
2, waist circumference or WHR
should be measured to identify people at
high cardiovascular and metabolic risk.
The relative contribution of general adi-
posity may, however, be more relevant in
severe obesity.
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